Literature DB >> 32687229

COVID-19 in children in Brunei Darussalam: Higher incidence but mild manifestations.

Shaji George1, Mohammad Salahuddin Ansari1, Anto Kalliath1, Mohammad Jawaid Khan1, Muhammad Syafiq Abdullah2,3, Rosmonaliza Asli2, Riamiza Natalie Momin2, Babu Ivan Mani3, Pui Lin Chong2, Vui Heng Chong2,3,4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32687229      PMCID: PMC7405023          DOI: 10.1002/jmv.26310

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
Dear Editor, Corona Virus Disease 2019 (COVID‐19) predominately affects the adult population and it is estimated that children account for only between 2% and 5% of all COVID‐19 cases. , , The manifestations in children are usually mild but severe manifestations have been reported. Here we share our experience in pediatric patients with COVID‐19. In Brunei Darussalam, all reverse transcriptase‐polymerase chain reaction (RT‐PCR) confirmed COVID‐19 cases were admitted to the National Isolation Centre for a minimum of 14 days. For the pediatric patients (≤12 years), we deviated slightly from our management protocol previously described, with an initial clinical assessment to decide on the need for investigations. To minimize trauma, blood investigations were only done when indicated. Patients were monitored with the Paediatric Early Warning Score. Swabbing for RT‐PCR was done on the 13th day of hospitalization as per protocol. If the test was positive, then this was repeated at 48 hours’ intervals. A negative result was followed by a repeat in 24 hours. Once two consecutive negatives were obtained and with clinical symptoms recovery, patients were discharged. Postdischarge, patients were issued a 14 days’ self‐isolation notice and were also monitored. On the 11th day, a repeat RT‐PCR was done, and patients were readmitted if they retested positive. As of 15th June 2020, there was a total of 141 confirmed COVID‐19 cases, of which 12 (8.5%) were in the pediatric population (median age 6 years [range: 6 months‐12 years] and seven boys and five girls). Summary of patients’ profiles, progress, and outcomes is shown in Table 1. All were categorized as mild COVID‐19. Four patients had comorbidities. All were diagnosed through contact tracing involving mostly family members who had traveled overseas. Overall 8 (66.7%) had mild symptoms, including one who developed symptoms after admission. Fever (50.0%) and cough (50.0%) were the most common symptoms. Only three (25%) had blood investigations. A chest radiograph was done in seven older patients and all were normal. One was treated with antibiotics. For symptomatic patients, symptoms resolution occurred by the fifth day of admission and all were discharged at a median of 14 days (range: 14‐25). None of our pediatric patients required specific treatment (lopinavir/ritonavir) for COVID‐19. One (case 2) was readmitted after discharge because of retesting positive along with his parents. At a median of 73 days (range: 48‐78) postdischarge, there were no sequelae or complications of COVID‐19.
Table 1

Characteristics, progress, and outcomes of patients

CaseAge (gender)Positive contactComorbid conditionsSymptoms on admissionLaboratoryManagementOutcome
112 y (M)FatherAutism overweightLow‐grade fever 1 dNot doneAcetaminophenDischarged after 22 d
25 y (M)FatherAutism obesityLow‐grade fever and mild cold symptoms for 1 dNot doneAcetaminophenDischarged after 22 d
39 mo (F)FatherMild cough and cold for 2 dNot doneAcetaminophenDischarged after 14 d
43 y (F)FatherAsymptomaticNot doneDischarged after 14 d
57 y (M)TeacherAsymptomaticNot doneDischarged after 14 d
612 y (M)Clinic with confirmed caseObesityAsymptomaticNot doneDischarged after 14 d
74 y (F)FatherMild cold symptoms 1 dNormal Blood culture −veIV antibiotics Fever (40°C) for 72 h AcetaminophenDischarged after 14 d
810 y (F)FatherLow‐grade fever and cough 1 dNot doneAcetaminophenDischarged after 14 d
96 mo (F)GrandparentAsymptomatic on admissionNot doneAcetaminophen Fever for 48 hDischarged after 14 d
1010 y (M)FatherMild cold and cough 1 dNormal blood culture −veFever during hospitalization for 48 h AcetaminophenDischarged after 14 d
113 y (M)FatherFever 3 d, mild cold, and loose stools 1 dNot doneDischarged after 25 d
1212 y (M)FatherObesity developmental delayAsymptomaticNormalAcetaminophenDischarged after 19 d

Abbreviations: d, day; F, female; h, hour; M, male; mo, month; y, year.

Characteristics, progress, and outcomes of patients Abbreviations: d, day; F, female; h, hour; M, male; mo, month; y, year. We reported a much higher incidence of COVID‐19 in children compared to what has been reported in the literature. Our higher rate may have been due to our aggressive surveillance and contact tracing resulting in high case identifications. To date, through a community serology survey, we had detected six positive cases out of 535 persons who had not been diagnosed with COVID‐19 indicating that we had missed a small proportion of patients. What has been reported in the literature may be underestimated given that only patients who have been tested were counted and, generally mild or asymptomatic cases were not tested. The clinical manifestations and disease course in children are generally mild as reported in the literature. , , Recent articles have reviewed the manifestations of COVID‐19 in children and another discussed the reasons for mild manifestations. All our patients had mild disease and did not require any specific treatment for COVID‐19. As our understanding increases, management protocols will continue to evolve. Even though a less aggressive management approach can be adopted, we must remain vigilant, monitor closely and investigate appropriately not just during hospitalizations, but also after discharge as delayed immune driven complications such as Kawasaki like syndrome have been reported. , In conclusion, we showed that the incidence of COVID‐19 in children in Brunei Darussalam is higher than reported, and in agreement with what has been published in the literature, manifestations are generally mild.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHORS CONTRIBUTIONS

All authors involved with care of patients and contributed to data collections. SG and VHC conceived the idea. SG and VHC drafted the first draft. All authors critically review the manuscript. VHC revised the manuscript, all authors approved the final version.

KEYWORDS

children, pediatric, SARS‐CoV‐2, severe respiratory distress syndrome
  8 in total

1.  SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children.

Authors:  Francesco Licciardi; Giulia Pruccoli; Marco Denina; Emilia Parodi; Manuela Taglietto; Sergio Rosati; Davide Montin
Journal:  Pediatrics       Date:  2020-05-21       Impact factor: 7.124

2.  Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes.

Authors:  Hui Peng; Ping Gao; Qiong Xu; Maochang Liu; Jing Peng; Yang Wang; Hua Xu
Journal:  J Clin Virol       Date:  2020-05-07       Impact factor: 3.168

3.  Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.

Authors:  Vui Heng Chong; Pui Lin Chong; Dhiya Metussin; Rosmonaliza Asli; Riamiza Natalie Momin; Babu Ivan Mani; Muhammad Syafiq Abdullah
Journal:  J Med Virol       Date:  2020-05-22       Impact factor: 2.327

4.  Cardiac dysfunction and thrombocytopenia-associated multiple organ failure inflammation phenotype in a severe paediatric case of COVID-19.

Authors:  Gwynne Latimer; Christiane Corriveau; Roberta L DeBiasi; Barbara Jantausch; Meghan Delaney; Cyril Jacquot; Michael Bell; Terry Dean
Journal:  Lancet Child Adolesc Health       Date:  2020-05-18

5.  Clinical Characteristics of COVID-19 Infection in Newborns and Pediatrics: A Systematic Review.

Authors:  Latif Panahi; Marzieh Amiri; Somaye Pouy
Journal:  Arch Acad Emerg Med       Date:  2020-04-18

6.  Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues.

Authors:  Seyed Mohammad Miri; Farshid Noorbakhsh; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  J Med Virol       Date:  2020-06-09       Impact factor: 20.693

Review 7.  Children with coronavirus disease 2019: A review of demographic, clinical, laboratory, and imaging features in pediatric patients.

Authors:  Xiaojian Cui; Tongqiang Zhang; Jiafeng Zheng; Jiayi Zhang; Ping Si; Yongsheng Xu; Wei Guo; Zihui Liu; Wenliang Li; Jia Ma; Cuicui Dong; Yongming Shen; Chunquan Cai; Sijia He
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 2.327

8.  Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults.

Authors:  Jonas F Ludvigsson
Journal:  Acta Paediatr       Date:  2020-04-14       Impact factor: 4.056

  8 in total
  2 in total

1.  Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis.

Authors:  Omar Irfan; Fiona Muttalib; Kun Tang; Li Jiang; Zohra S Lassi; Zulfiqar Bhutta
Journal:  Arch Dis Child       Date:  2021-02-16       Impact factor: 3.791

2.  Pediatric COVID-19 Risk Factors in Southeast Asia-Singapore and Malaysia: A Test-Negative Case-Control Study.

Authors:  Judith Ju Ming Wong; Chin Seng Gan; Sanghvi Heli Kaushal; Soo Lin Chuah; Rehena Sultana; Natalie Woon Hui Tan; Kah Peng Eg; Koh Cheng Thoon; Jan Hau Lee; Chee Fu Yung
Journal:  Am J Trop Med Hyg       Date:  2022-02-15       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.